RNS Number : 1804E
Thalia Therapeutics PLC
13 May 2026

13 May 2026

Thalia Therapeutics plc

("Thalia" or the "Company")

CEO Interview: Advancing Thalia's RNA Therapeutics Strategy

Thalia Therapeutics plc (AIM: THAT), a biotech company developing innovative RNA therapeutics, is pleased to announce the release of a new video interview with Chief Executive Officer, Dr David Solomon.

In the interview, Dr Solomon discusses the Company's strategic transition to Thalia Therapeutics, the rationale behind its increasing focus on high-value RNA therapeutics, the continued development of Nuvec®, and the opportunities the Company sees in cardiovascular disease and oncology.

The interview is available to watch via the Company's website at: https://investors.thaliatx.com/activity-updates

- Ends -

For more information please contact:

Thalia Therapeutics plc
Dr David H Solomon, Chief Executive Officer — Via Thalia Investor Hub https://investors.thaliatx.com/link/P4zkAe

SP Angel Corporate Finance LLP — Tel: +44 (0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Turner Pope Investments (TPI) Limited — Tel: +44 (0)20 3657 0050
Joint Broker
Andy Thacker
Guy McDougall

Northstar Communications — Tel: +44 (0)20 7183 2463
Investor relations and Communications
Sarah Hollins

Cohesion Bureau — Tel: +44 (0)7483 284853
Investor relations and Communications
Mary-Ann Chang

About Thalia Therapeutics plc

Thalia Therapeutics plc is a pre-clinical biotech company focused on developing innovative RNA therapeutics and novel delivery systems to address high unmet needs in global healthcare.

RNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. Thalia Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets.

Nuvec® addresses multiple challenges associated with RNA therapeutics manufacturing and delivery, including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to enable oral delivery, avoidance of unwanted immune responses, and excellent stability and storage.

For further information visit www.thaliatx.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAGPUQUAUPQGUW